Avoro Capital Advisors Llc Acquires 750,000 Shares of Immunomedics, Inc. (IMMU) Stock
Immunomedics, Inc. (NASDAQ:IMMU) insider Avoro Capital Advisors Llc bought 750,000 shares of Immunomedics stock in a transaction dated Wednesday, May 15th. The shares were acquired at an average cost of $15.11 per share, with a total value of $11,332,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Avoro Capital Advisors Llc also recently made the following trade(s):
- On Monday, May 13th, Avoro Capital Advisors Llc acquired 500,000 shares of Immunomedics stock. The stock was purchased at an average cost of $15.07 per share, with a total value of $7,535,000.00.
NASDAQ IMMU traded up $0.95 during mid-day trading on Thursday, hitting $15.88. The stock had a trading volume of 139,000 shares, compared to its average volume of 3,111,805. Immunomedics, Inc. has a twelve month low of $11.55 and a twelve month high of $27.33. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.89 and a current ratio of 7.89. The company has a market cap of $2.95 billion, a P/E ratio of -15.50 and a beta of 1.97.
Institutional investors and hedge funds have recently modified their holdings of the business. Exane Derivatives acquired a new stake in shares of Immunomedics in the 4th quarter worth $32,000. Karp Capital Management Corp acquired a new stake in shares of Immunomedics in the 4th quarter worth $33,000. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Immunomedics by 5,473.5% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,861 shares during the last quarter. Global Retirement Partners LLC increased its stake in shares of Immunomedics by 215.7% in the 1st quarter. Global Retirement Partners LLC now owns 1,910 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 1,305 shares during the last quarter. Finally, Cornerstone Advisors Inc. acquired a new stake in shares of Immunomedics in the 1st quarter worth $40,000. 86.11% of the stock is owned by institutional investors and hedge funds.
IMMU has been the subject of several recent research reports. BidaskClub downgraded Immunomedics from a “buy” rating to a “hold” rating in a research note on Wednesday, February 13th. HC Wainwright set a $28.00 price objective on Immunomedics and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Zacks Investment Research downgraded Immunomedics from a “hold” rating to a “sell” rating in a research note on Thursday, January 24th. ValuEngine downgraded Immunomedics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, April 24th. Finally, Cowen reissued a “buy” rating and issued a $30.00 price objective on shares of Immunomedics in a research note on Friday, January 18th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $28.45.
TRADEMARK VIOLATION WARNING: “Avoro Capital Advisors Llc Acquires 750,000 Shares of Immunomedics, Inc. (IMMU) Stock” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2019/05/16/avoro-capital-advisors-llc-acquires-750000-shares-of-immunomedics-inc-immu-stock.html.
Immunomedics Company Profile
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
Further Reading: Hedge Funds – Risk or Reward?
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.